SOT

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Tuesday, March 12, 2024
Abstract, Chlorine, Survival, SOT, University, Doctor of Philosophy, MD, Code, FAHA, Society, Translation, Safety, Tokyo Stock Exchange, ALI, Edema

In this study, single-dose and multi-dose treatments were evaluated.

Key Points: 
  • In this study, single-dose and multi-dose treatments were evaluated.
  • The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • Additional endpoints included survival, lung mechanics, lung injury, and edema formation evaluated by chest x-ray.
  • Cl2 gas concentration of 210 ppm x 30 min was expected to result in a 20 - 30% mortality rate (Fukuda 2015).

A paper showing that exposure to fragrance ingredients is extremely low wins coveted Society of Toxicology award

Retrieved on: 
Tuesday, March 19, 2024
Crème, DST, Top Ten, Science, TTC, SOT, Running, Risk assessment, Mentorship, Abstract, Commercial director, Skin, Toxicology, Research institute

SALT LAKE CITY, March 19, 2024 /PRNewswire/ -- A collaborative poster presentation on fragrance ingredient exposure by The Research Institute for Fragrance Materials, Inc. (RIFM.org) and scientific modeling and data analytics company Creme Global (cremeglobal.com) earned its presenters a prestigious Top Ten Presentation Award during the Risk Session of SOT's 63rd Annual Meeting and ToxExpo, held in Salt Lake City, Utah, March 10-14th, 2024. Some 300 abstracts were in the running.

Key Points: 
  • I'm proud of how expertly RIFM's scientists communicate our critical fragrance safety science to other scientists."
  • "And it was especially rewarding to receive the Risk Assessment Specialty Section Top Ten Abstract Award for our low-exposure paper."
  • The study authors compared the fragrance exposure of the highest-end product users to the internationally recognized Threshold of Toxicological Concern (TTC) and Dermal Sensitization Threshold (DST) to determine a realistic understanding of consumer exposure to fragrance.
  • "RIFM has set the gold standard in ingredient risk assessment, gathering and sharing real usage data."

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Retrieved on: 
Wednesday, March 6, 2024
Neuropharmacology, Pharmacology, Algorithm, Microelectrode array, SOT, Artificial intelligence, Data management, Product management, Society of Toxicology, Salt Palace, Electrophysiology, Society, Organoid, Harvard Bioscience, Safety, Area studies, DSI, ChromeOS, HBIO, MEA, Machine learning, Research, Mesh, Environment, Online shopping

Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

Key Points: 
  • Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
  • The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.
  • The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
  • The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology.

BioIVT to Showcase Leading Products for Toxicological Studies at the SOT ToxExpo 2024

Retrieved on: 
Thursday, March 7, 2024
Metabolism, SOT, Doctor of Philosophy, Research, Prodrug, Drug development, DDI, Society of Toxicology, Hall, Immune system, Learning, Cell, Poster, CES, Biotransformation, ADME, Medical device

WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .

Key Points: 
  • WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .
  • "The BioIVT team attending SOT includes experts from across our product portfolios.
  • We look forward to meeting with research colleagues and learning how we can support their programs," he added.
  • Visit BioIVT on the show floor at booth #1509 or schedule a time to connect with us and learn more: https://bioivt.com/about/events?entry=SOT+ToxExpo+2024

Systemic Bio to Present Innovative Human-relevant Datasets from h-VIOS™ Platform at SOT and AACR 2024 Annual Meetings

Retrieved on: 
Thursday, February 8, 2024
Abstract, Society of Toxicology, DMPK, Therapy, 3D Systems, CYP, AACR, SOT, Liver injury, Tissue, Liver, Urea, Research, P450, Annual general meeting

HOUSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Systemic Bio™ , a 3D Systems (NYSE:DDD) company, is excited to announce the acceptance of two abstracts for presentation at the prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt Lake City, March 10-14, 2024) and American Association for Cancer Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).

Key Points: 
  • HOUSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Systemic Bio™ , a 3D Systems (NYSE:DDD) company, is excited to announce the acceptance of two abstracts for presentation at the prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt Lake City, March 10-14, 2024) and American Association for Cancer Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).
  • At the SOT 2024 meeting, Systemic Bio will present its latest research on an advanced liver model that demonstrates several-fold enhanced albumin production, CYP (cytochrome P450) activity, and urea production compared to traditional models.
  • The second abstract, accepted for AACR 2024, showcases a novel model that simultaneously assesses on-target anti-tumor therapeutic efficacy and off-target liver injury of therapeutics across different modalities.
  • To delve deeper into this research, all conference attendees and fellow researchers can visit booth #4452 to engage directly with Systemic Bio’s team and discover the full potential of the h-VIOS platform.

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Rituximab, Survival, European, EBV, Graft-versus-host disease, MHRA, The Lancet, Patient, FDA, EMA, SOT, Cytokine release syndrome, Society, ATRA, ASH, HCT, Cancer, BLA, Lymphoproliferative disorders, Epstein–Barr virus

22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).

Key Points: 
  • 22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).
  • The median duration of response was 23.0 months and the median overall survival was 18.4 months.
  • These interim data were previously presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
  • All this resonates perfectly with our purpose ‘every time we care for a single person, we make the whole world better,’” said Núria Perez-Cullell, Director of Medical Affairs, Patients & Consumers at Pierre Fabre Laboratories.

Queen Mother Hosts Chef Nak in Celebration of Cambodian Culinary Excellence

Retrieved on: 
Tuesday, January 16, 2024
Learning, Oval, Social media, Lamo, Multimedia, Queen mother, Khmer, Oval Office, Royal corgis, Television, SOT, Film industry

The Queen Mother continues to inspire and empower future generations, encouraging them to preserve and improve Cambodian cuisine.

Key Points: 
  • The Queen Mother continues to inspire and empower future generations, encouraging them to preserve and improve Cambodian cuisine.
  • She recognizes Chef Nak and her team's important role in restoring culinary traditions shattered by war, especially the restoration of royal cuisine.
  • At the meeting, Her Majesty the Queen Mother described her meeting with Chef Nak and her team as family-like.
  • During her visit with the Queen Mother, Chef Nak expressed heartfelt gratitude for this honor and pledged to elevate Cambodian cuisine on the global stage.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Thursday, December 21, 2023
Translation, Tokyo Stock Exchange, SOT, Administration, Chlorine, MD, Doctor of Philosophy, Human services, Society, Code, Poster, FAHA, University

LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.

Key Points: 
  • LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.
  • The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.
  • The presentation details are as follows:
    Abstract Number / Poster Board number: 4296 / P871
    This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

Retrieved on: 
Thursday, December 21, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Transplant, SOT, CDE, CMV, Cidofovir, Incidence, Hospital, Week, NMPA, Ganciclovir, Infection, European, National Medical Products Administration, Cytomegalovirus, Valganciclovir, Patient, Safety, Foscarnet

Takeda ( TSE:4502/NYSE:TAK ) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
  • LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication.
  • LIVTENCITY was granted Breakthrough Therapy Designation by China Center for Drug Evaluation (CDE) in 2021.
  • “This approval will help redefine the CMV treatment landscape for transplant patients in China and is a positive step forward toward addressing an unmet need for this community.”
    The NMPA approval is based on the results of the Phase 3 SOLSTICE trial, which evaluated the safety and efficacy of maribavir versus conventional antiviral therapies – ganciclovir, valganciclovir, cidofovir or foscarnet – for the treatment of patients with CMV infection/disease refractory* to prior therapies.

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Retrieved on: 
Wednesday, November 29, 2023
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, CNS, ATRA, Epstein–Barr virus, Safety, Partial-response maximum-likelihood, PST, Disease, Northwest Biotherapeutics, ESMO, HCT, Patient, CET, ORR, SOT, Cancer, Symantec Endpoint Protection, PTLD, Neurotoxicity, Congress, Central nervous system, EBV, TTR, OS, PR, Vaccine, Pharmaceutical industry

These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.

Key Points: 
  • These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.
  • “We’re pleased to share new multicenter data, including the first results from our ongoing multicohort EBVision trial and first clinical trial report of treatment with tab-cel in the first line setting.
  • The estimated one-year overall survival (OS) rate was 70.6% (95% CI: 43.0, 86.6) for all patients.
  • Date & Time: December 7, 2023, at 2:15 - 3:45 p.m. CET / 5:15 - 6:45 a.m. PST